Last reviewed · How we verify
NCT05469698: PAD
Onsite Tobacco Cessation Treatment for Patients With PAD
NA trial testing Tobacco Treatment Research Program Standard Care in Tobacco Cessation in 15 participants. Status unknown.
30 June 2023
Quick facts
| Lead sponsor | University of Oklahoma |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 15 |
| Start date | 16 August 2022 |
| Primary completion | 30 June 2023 |
| Estimated completion | 31 July 2024 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Tobacco Treatment Research Program Standard Care
Conditions studied
- Tobacco Cessation — all drugs for Tobacco Cessation →
- Peripheral Artery Disease — all drugs for Peripheral Artery Disease →
Sponsor
University of Oklahoma
Who can join
Adults 18 to 100, any sex, with Tobacco Cessation or Peripheral Artery Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Tobacco cessation treatment is needed for individuals with peripheral artery disease (PAD) to improve symptoms, lower cardiovascular risk, and prevent amputation. While such treatment is effective, many PAD patients do not receive cessation therapy. Participants will receive nicotine replacement therapy, counseling, and and complete questionnaires. We hypothesize that integrating tobacco cessation services into a dedicated PAD clinic (OU CVI Limb Preservation Clinic) can improve tobacco cessation rates and improve PAD-related health outcomes in this at risk population.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05469698
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Tobacco Cessation
Currently open trials in the same condition.
- NCT07098065 — Health Warnings and Counseling for Smoking Cessation · NA · recruiting
- NCT07148232 — Extended Intervention for Tobacco Use (EXIT) for People Experiencing Homelessness · Phase 4 · recruiting
- NCT05429892 — FRESH Delivers: An Innovative Approach to Reducing Tobacco Use Among Rural Smokers · NA · recruiting
- NCT04865276 — Adaptation and Evaluation of a Culturally and Gender Relevant Tobacco Cessation Among Women in Brazil: An Integrated mHe · NA · recruiting
Other University of Oklahoma trials
Trials by the same sponsor.
- NCT07219706 — Dietary Fiber and Time Restricted Eating · NA · recruiting
- NCT07494773 — Topical Methylene Blue-Photodynamic Therapy (MB-PDT) for Burn Wound Infection · Phase 1, PHASE2 · not yet recruiting
- NCT07014605 — Smoking Cessation Program for Lao People With HIV · NA · not yet recruiting
- NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
- NCT07491653 — Fiber mHealth Intervention for Prediabetes · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05469698 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Oklahoma
- Last refreshed: 15 February 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05469698.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing